4CPS-054 Persistence of inhibitors of interleukin-17 (Anti-IL-17) for the treatment of moderate to severe psoriasis (MSPS) in the routine clinical practice conditions

<h3>Background and Importance</h3> Anti-IL-17 have emerged as safe and effective options for the treatment of msPs <h3>Aim and Objectives</h3> Evaluate the persistence of anti-IL-17 (secukinumab, ixekizumab, bimekizumab and brodalumab) in patients with msPs. Secondarily, these patients’ clinical outcomes and health-related quality of life (HRQL) and the safety profile were also assessed. <h3>Material and Methods</h3> Retrospective observational study from January 2020 to June 2024. Patients with msPs receiving anti-IL-17 were included. Demographic (sex, age) and clinical data (previous treatments, optimised therapy and baseline Psoriasis Area Severity Index (PASI)) were collected from the digital medical record. Non-persistence was defined as treatment discontinuation or a treatment gap &gt; 90 days. The cumulative probability of treatment persistence was analysed by Kaplan-Meier method. Secondary endpoint: clinical outcomes (PASI90 response at 1 year), change in HRQL through dermatology life quality index (DLQI) at 1 year, and safety profile. <h3>Results</h3> 68 patients were included (40.2% women), 29 received secukinumab, 33 ixekizumab, 4 bimekizumab and 2 brodalumab. Mean age was 70.4 years. 81.9% received biologic therapies before and 94.4% conventional systemic treatment. Dose interval was extended only for 7 secukinumab patients (&gt;4weeks). The cumulative probability of secukinumab, ixekizumab, bimekizumab and brodalumab treatment persistence was 73.5% (95%IC 57.3–89.6), 41.6% (95%IC 31.7–51.5), 8.3% (95%IC 3.5–13.4) and 22.9% (95%IC 0–46.4) at 1 year. Secondary endpoint: the median baseline PASI was 8.0, 6.25, 5.50 and 4.0 respectively. 62.1%, 48.5%, 25% and 0% of patients respectively achieved PASI90 at 1 year. 48.3%, 27.3%, 50% and 100% of patients respectively achieved a minimal clinically significant difference (&gt;4-point reduction) in DLQI at 1 year. 3 patient with secukinumab experienced adverse reactions (fatigue, gastrointestinal and infections), 8 with ixekizumab (3-gastrointestinal, 1-infections, 2-fatigue and 2-injection site reactions) and 1 patient with bimekizumab (allergy). <h3>Conclusion and Relevance</h3> Our cohort shows a moderate persistence rate and PASI improvement at 1 year with secukinumab; the other anti-IL-17 show low clinical profits. High benefit in improving HRQL was reached with bimekizumab and brodalumab while secukinumab and ixekizumab showed modest results. No important adverse reactions were found, without treatment withdrawals. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest